🇺🇸 FDA
Pipeline program

Ublituximab

HP-00113916

Unknown small_molecule active

Quick answer

Ublituximab for Multiple Sclerosis (MS) - Relapsing-remitting is a Unknown program (small_molecule) at TG THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
TG THERAPEUTICS, INC.
Indication
Multiple Sclerosis (MS) - Relapsing-remitting
Phase
Unknown
Modality
small_molecule
Status
active

Clinical trials